Your browser doesn't support javascript.
loading
Efficacy and safety of oral methazolamide in patients with type 2 diabetes: a 24-week, placebo-controlled, double-blind study.
Simpson, Richard W; Nicholson, Geoffrey C; Proietto, Joseph; Sarah, Alana; Sanders, Kerrie M; Phillips, Gabrielle; Chambers, Jo; MacGinley, Rob; Orford, Neil; Walder, Ken; Krippner, Guy; Skoff, Kathy; Wacher, Vincent J.
Afiliación
  • Simpson RW; Box Hill Hospital, Box Hill, Victoria, Australia.
  • Nicholson GC; Department of Clinical and Biomedical Sciences, Geelong Hospital, University of Melbourne, Melbourne, Victoria, Australia.
  • Proietto J; Heidelberg Repatriation Hospital, University of Melbourne, Melbourne, Victoria, Australia.
  • Sarah A; Clinical Trial Unit, Department of Medicine, Barwon Health, Geelong, Victoria, Australia.
  • Sanders KM; Department of Clinical and Biomedical Sciences, Geelong Hospital, University of Melbourne, Melbourne, Victoria, Australia.
  • Phillips G; Box Hill Hospital, Box Hill, Victoria, Australia.
  • Chambers J; Clinical Trial Unit, Department of Medicine, Barwon Health, Geelong, Victoria, Australia.
  • MacGinley R; Deakin University, Geelong, Victoria, Australia.
  • Orford N; Department of Epidemiology and Preventive Medicine, Barwon Health/Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Victoria, Australia.
  • Walder K; Deakin University, Geelong, Victoria, Australia.
  • Krippner G; Verva Pharmaceuticals, Ltd., Southbank, Victoria, Australia.
  • Skoff K; Verva Pharmaceuticals, Ltd., Southbank, Victoria, Australia.
  • Wacher VJ; Verva Pharmaceuticals, Ltd., Southbank, Victoria, Australia. vwacher@vervapharma.com.
Diabetes Care ; 37(11): 3121-3, 2014 Nov.
Article en En | MEDLINE | ID: mdl-25125506
OBJECTIVE: To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes. RESEARCH DESIGN AND METHODS: This double-blind, placebo-controlled study randomized 76 patients to oral methazolamide (40 mg b.i.d.) or placebo for 24 weeks. The primary efficacy end point for methazolamide treatment was a placebo-corrected reduction in HbA1c from baseline after 24 weeks (ΔHbA1c). RESULTS: Mean ± SD baseline HbA1c was 7.1 ± 0.7% (54 ± 5 mmol/mol; n = 37) and 7.4 ± 0.6% (57 ± 5 mmol/mol; n = 39) in the methazolamide and placebo groups, respectively. Methazolamide treatment was associated with a ΔHbA1c of -0.39% (95% CI -0.82, 0.04; P < 0.05) (-4.3 mmol/mol [-9.0, 0.4]), an increase in the proportion of patients achieving HbA1c ≤6.5% (48 mmol/mol) from 8 to 33%, a rapid reduction in alanine aminotransferase (∼10 units/L), and weight loss (2%) in metformin-cotreated patients. CONCLUSIONS: Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Anhidrasa Carbónica / Diabetes Mellitus Tipo 2 / Metazolamida Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Care Año: 2014 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Anhidrasa Carbónica / Diabetes Mellitus Tipo 2 / Metazolamida Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Care Año: 2014 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos